Accelerate your research with our state-of-the-art facility. We offer comprehensive, industry-standard screening capabilities combined with innovative assay development — all designed to uncover the next big discovery in basic research and pharmacology.
Why Choose HTS?
Comprehensive Screening Services
- High throughput screening of drug & compound libraries
- Functional genomic screening (siRNA, shRNA, ORFeome, CRISPR)
- Phenotypic screening with high-content imaging & machine learning
Advanced Automation & Instrumentation
- Liquid handlers & robotic arms for seamless automation
- Multi-mode & kinetic plate readers for versatile assay analysis
- High-content imaging & analysis for 2D & 3D culture models
Expert Support & Custom Solutions
- Full-service access or walk-up use with personalized training
- SAR & lead optimization with VICB Molecular Design & Synthesis Center (V-MDSC)
- Compound management & informatics solutions
Extensive Compound & Genomic Libraries
- 350,000+ diverse small molecules, including FDA-approved & NIH clinical candidates
- Whole genome siRNA, shRNA, ORFeome and CRISPR-arrayed libraries.
Types of Services
Instrumentation
The HTS facility houses state-of-the-art liquid handlers, multi-mode plate readers that can be integrated into screening systems for automated HTS applications, label-free, alpha screen, scintillation proximity, and high-content screening technologies, and more. We staff a full-time engineer to ensure the instrumentation meets or exceeds industry specifications for operation.
Compounds
We have a small-molecule library of over 160,000 selected ‘drug-like’ compounds, primarily from ChemBridge and ChemDiv. Along with the Vanderbilt library, we also house a 100,000 compound library through the Molecular Libraries Screening Center Network (MLSCN) and several smaller libraries 200-2,000 compounds that include the SPECTRUM collection, NIH clinical collection, biolipids, and kinase inhibitor collections.
Assays
Our facility specializes in cellular-based assays as well as in vitro molecular assays, particularly G-protein coupled receptors (GPCRs), ion channels, disease targets, microbial targets, viral targets, and cancer targets. However, we are able to handle a wide variety of experimental setups, including cytotoxicity, enzyme reactions, immunochemistry, imaging, genomic screening, RNAi screening, and some DMPK assays.
Featured Publication
Modeling patient drug exposure profiles in vitro to narrow the valley of death
Nature Reviews Bioengineering. (2024). Catherine S. Leasure & Gregor Neuert
The current drug development pipeline is time-consuming, costly and inefficient. To better model interactions between pharmaceuticals and human physiology and, thus, increase the likelihood of drug success in clinical trials, the effect of pharmacokinetic drug profiles on cellular behavior should be tested early in drug development.